Clene secures fourth-year NIH subaward with NYU for ALS program

Clene Inc. disclosed in an 8-K filing that it entered into a new funding amendment on October 15, 2026, extending support under a multi-year federal grant tied to its ALS treatment program.

The company and its wholly owned subsidiary, Clene Nanomedicine, Inc., had previously announced a four-year, $45.1 million grant from the National Institute of Health, awarded on October 5, 2023, in collaboration with Synapticure, described as a neurology specialty health clinic.¹ Funding for the grant has moved through a series of subaward agreements, first with Columbia University as prime awardee for the first two years, then with New York University starting with the third year.

Under the agreement disclosed in this filing, Clene and NYU amended the subaward to cover a fourth year of funding, providing up to $7.2 million for the period running from September 1, 2026 through August 31, 2027.¹ The filing noted that terms of the subaward beyond the new funding period, as previously disclosed in the company's March 16, 2026 Form 8-K, continue to apply.¹

Clene said the underlying NIH grant funds an Expanded Access Program for its drug candidate CNM-Au8 in the treatment of amyotrophic lateral sclerosis, and was awarded under the "Accelerating Access to Critical Therapies for ALS Act."¹

The amendment was filed as an exhibit to the 8-K, with the company noting the agreement's full text should be consulted for complete terms. The filing was signed by Robert Etherington, Clene's President and Chief Executive Officer, and dated October 20, 2026.